Recent advances in the development of a chemically synthesised anti-malarial vaccine

Bibliography

• WHO. World malaria report. WHO global malaria programme. 2013;2013
   Google Scholar
• Patarroyo ME, Amador R, Clavijo P, et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 1988;332(6160):158-61
   PubMed Web of Science ®Google Scholar
• Zavala F, Tam JP, Barr PJ, et al. Synthetic peptide vaccine confers protection against murine malaria. J Exp Med 1987;166(5):1591-6
   PubMed Web of Science ®Google Scholar
• Nussenzweig RS, Vanderberg J, Most H, et al. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature 1967;216(5111):160-2
   PubMed Web of Science ®Google Scholar
• Noya O, Gabaldon Berti Y, Alarcon de Noya B, et al. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J Infect Dis 1994;170(2):396-402
   PubMed Web of Science ®Google Scholar
• Epstein JE, Tewari K, Lyke KE, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 2011;334(6055):475-80
   PubMed Web of Science ®Google Scholar
• Mahajan B, Berzofsky JA, Boykins RA, et al. Multiple antigen peptide vaccines against Plasmodium falciparum malaria. Infect Immun 2010;78(11):4613-24
   PubMed Web of Science ®Google Scholar
• Seder RA, Chang LJ, Enama ME, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013;341(6152):1359-65
   PubMed Web of Science ®Google Scholar
• Hill AV. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci 2011;366(1579):2806-14
   PubMed Web of Science ®Google Scholar
• Casares S, Richie TL. Immune evasion by malaria parasites: a challenge for vaccine development. Curr Opin Immunol 2009;21(3):321-30
   PubMed Web of Science ®Google Scholar
• Patarroyo ME, Bermudez A, Patarroyo MA. Structural and immunological principles leading to chemically synthesized, multiantigenic, multistage, minimal subunit-based vaccine development. Chem Rev 2011;111(5):3459-507
   PubMed Web of Science ®Google Scholar
• Hisaeda H, Yasutomo K, Himeno K. Malaria: immune evasion by parasites. Int J Biochem Cell Biol 2005;37(4):700-6
   PubMed Web of Science ®Google Scholar
• Moisa AA, Kolesanova EF. Synthetic peptide vaccines biochemistry (Moscow) supplement series B. Biochemical Chemistry 2010;4(4):321-32
   Google Scholar
• Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007;6(5):404-14
   PubMed Web of Science ®Google Scholar
• Vaughan K, Blythe M, Greenbaum J, et al. Meta-analysis of immune epitope data for all Plasmodia: overview and applications for malarial immunobiology and vaccine-related issues. Parasite Immunol 2009;31(2):78-97
   PubMed Web of Science ®Google Scholar
• Patarroyo ME, Romero P, Torres ML, et al. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 1987;328(6131):629-32
   PubMed Web of Science ®Google Scholar
• Amador R, Moreno A, Murillo LA, et al. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. J Infect Dis 1992;166(1):139-44
   PubMed Web of Science ®Google Scholar
• Patarroyo G, Franco L, Amador R, et al. Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years. Vaccine 1992;10(3):175-8
   PubMed Web of Science ®Google Scholar
• Alonso PL, Smith T, Schellenberg JR, et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994;344(8931):1175-81
   PubMed Web of Science ®Google Scholar
• Sempertegui F, Estrella B, Moscoso J, et al. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. Vaccine 1994;12(4):337-42
   PubMed Web of Science ®Google Scholar
• Valero MV, Amador R, Aponte JJ, et al. Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia. Vaccine 1996;14(15):1466-70
   PubMed Web of Science ®Google Scholar
• Acosta CJ, Galindo CM, Schellenberg D, et al. Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania. Trop Med Int Health 1999;4(5):368-76
   PubMed Web of Science ®Google Scholar
• D’Alessandro U, Leach A, Drakeley CJ, et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 1995;346(8973):462-7
   PubMed Web of Science ®Google Scholar
• Perrin LH, Simitsek P, Fasani-Ghersa P. Asexual blood stage vaccines: from merozoites to peptides. Trans R Soc Trop Med Hyg 1989;83(Suppl):53-6
   PubMedGoogle Scholar
• Merrifield R. Solid phase peptide synthesis. I the synthesis of a tetrapeptide. J Am Chem Soc 1963;85:2149
   Web of Science ®Google Scholar
• Arnon R. Chemically defined antiviral vaccines. Annu Rev Microbiol 1980;34:593-618
   PubMed Web of Science ®Google Scholar
• Cheung A, Leban J, Shaw AR, et al. Immunization with synthetic peptides of a Plasmodium falciparum surface antigen induces antimerozoite antibodies. Proc Natl Acad Sci USA 1986;83(21):8328-32
   PubMed Web of Science ®Google Scholar
• Houghten RA. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA 1985;82(15):5131-5
   PubMed Web of Science ®Google Scholar
• Boman HG, Wade D, Boman IA, et al. Antibacterial and antimalarial properties of peptides that are cecropin-melittin hybrids. FEBS Lett 1989;259(1):103-6
   PubMed Web of Science ®Google Scholar
• Francis MJ, Fry CM, Rowlands DJ, et al. Qualitative and quantitative differences in the immune response to foot-and-mouth disease virus antigens and synthetic peptides. J Gen Virol 1988;69(Pt 10):2483-91
   PubMed Web of Science ®Google Scholar
• Shinnick TM, Sutcliffe JG, Green N, et al. Synthetic peptide immunogens as vaccines. Annu Rev Microbiol 1983;37:425-46
   PubMed Web of Science ®Google Scholar
• Olive C, Toth I, Jackson D. Technological advances in antigen delivery and synthetic peptide vaccine developmental strategies. Mini Rev Med Chem 2001;1(4):429-38
   PubMedGoogle Scholar
• Meloen RH, Langeveld JP, Schaaper WM, et al. Synthetic peptide vaccines: unexpected fulfilment of discarded hope? Biologicals 2001;29(3-4):233-6
   PubMed Web of Science ®Google Scholar
• Arnon R, Van Regenmortel MH. Structural basis of antigenic specificity and design of new vaccines. FASEB J 1992;6(14):3265-74
   PubMed Web of Science ®Google Scholar
• McAnally JL, Xu L, Villain M, et al. The role of adjuvants in the efficacy of a peptide vaccine for myasthenia gravis. Exp Biol Med 2001;226(4):307-11
   Web of Science ®Google Scholar
• Wang CY, Chang TY, Walfield AM, et al. Effective synthetic peptide vaccine for foot-and-mouth disease in swine. Vaccine 2002;20(19-20):2603-10
   PubMed Web of Science ®Google Scholar
• Kan SC, Yamaga KM, Kramer KJ, et al. Plasmodium falciparum: protein antigens identified by analysis of serum samples from vaccinated Aotus monkeys. Infect Immun 1984;43(1):276-82
   PubMed Web of Science ®Google Scholar
• Dubois P, Dedet JP, Fandeur T, et al. Protective immunization of the squirrel monkey against asexual blood stages of Plasmodium falciparum by use of parasite protein fractions. Proc Natl Acad Sci U S A 1984;81(1):229-32
   PubMed Web of Science ®Google Scholar
• Collins WE, Anders RF, Pappaioanou M, et al. Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum. Nature 1986;323(6085):259-62
   PubMed Web of Science ®Google Scholar
• Siddiqui WA. An effective immunization of Aotus trivirgatus monkeys against Plasmodium falciparum: a research note. Bull World Health Organ 1977;55(2-3):403
   PubMed Web of Science ®Google Scholar
• Zavala F, Tam JP, Hollingdale MR, et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 1985;228(4706):1436-40
   PubMed Web of Science ®Google Scholar
• Carcaboso AM, Hernandez RM, Igartua M, et al. Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66. Int J Pharm 2003;260(2):273-82
   PubMed Web of Science ®Google Scholar
• Carcaboso AM, Hernandez RM, Igartua M, et al. Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine 2004;22(11-12):1423-32
   PubMed Web of Science ®Google Scholar
• Mata E, Igartua M, Hernandez RM, et al. Comparison of the adjuvanticity of two different delivery systems on the induction of humoral and cellular responses to synthetic peptides. Drug Deliv 2010;17(7):490-9
   PubMed Web of Science ®Google Scholar
• Rosas JE, Hernandez RM, Gascon AR, et al. Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66. Vaccine 2001;19(31):4445-51
   PubMed Web of Science ®Google Scholar
• Rosas JE, Pedraz JL, Hernandez RM, et al. Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres. Vaccine 2002;20(13-14):1707-10
   PubMed Web of Science ®Google Scholar
• Tanner M, Teuscher T, Alonso PL. SPf66-The First Malaria Vaccine. Parasitol Today 1995;11(1):10-13
   Google Scholar
• Amador R, Moreno A, Valero V, et al. The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity. Vaccine 1992;10(3):179-84
   PubMed Web of Science ®Google Scholar
• Valero MV, Amador LR, Galindo C, et al. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 1993;341(8847):705-10
   PubMed Web of Science ®Google Scholar
• Graves P, Gelband H. Vaccines for preventing malaria (SPf66). Cochrane Database Syst Rev 2006(2):CD005966
   Google Scholar
• Calvo M, Guzman F, Perez E, et al. Specific interactions of synthetic peptides derived from P. falciparum merozoite proteins with human red blood cells. Pept Res 1991;4(6):324-33
   PubMedGoogle Scholar
• Rodriguez LE, Curtidor H, Urquiza M, et al. Intimate molecular interactions of P. falciparum merozoite proteins involved in invasion of red blood cells and their implications for vaccine design. Chem Rev 2008;108(9):3656-705
   PubMed Web of Science ®Google Scholar
• Curtidor H, Vanegas M, Alba MP, et al. Functional, immunological and three-dimensional analysis of chemically synthesised sporozoite peptides as components of a fully-effective antimalarial vaccine. Curr Med Chem 2011;18(29):4470-502
   PubMed Web of Science ®Google Scholar
• Garcia JE, Puentes A, Patarroyo ME. Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design. Clin Microbiol Rev 2006;19(4):686-707
   PubMed Web of Science ®Google Scholar
• Rodriguez LE, Urquiza M, Ocampo M, et al. Plasmodium falciparum EBA-175 kDa protein peptides which bind to human red blood cells. Parasitology 2000;120(Pt 3):225-35
   PubMed Web of Science ®Google Scholar
• Urquiza M, Rodriguez LE, Suarez JE, et al. Identification of Plasmodium falciparum MSP-1 peptides able to bind to human red blood cells. Parasite Immunol 1996;18(10):515-26
   PubMed Web of Science ®Google Scholar
• Rudensky A, Preston-Hurlburt P, Hong SC, et al. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991;353(6345):622-7
   PubMed Web of Science ®Google Scholar
• Hunt DF, Michel H, Dickinson TA, et al. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 1992;256(5065):1817-20
   PubMed Web of Science ®Google Scholar
• Brown JH, Jardetzky TS, Gorga JC, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993;364(6432):33-9
   PubMed Web of Science ®Google Scholar
• Young MD, Porter JAJr, Johnson CM. Plasmodium vivax transmitted from man to monkey to man. Science 1966;153(3739):1006-7
   PubMed Web of Science ®Google Scholar
• Diaz D, Daubenberger CA, Zalac T, et al. Sequence and expression of MHC-DPB1 molecules of the New World monkey Aotus nancymaae, a primate model for Plasmodium falciparum. Immunogenetics 2002;54(4):251-9
   PubMed Web of Science ®Google Scholar
• Diaz OL, Daubenberger CA, Rodriguez R, et al. Immunoglobulin kappa light-chain V, J, and C gene sequences of the owl monkey Aotus nancymaae. Immunogenetics 2000;51(3):212-18
   PubMed Web of Science ®Google Scholar
• Suarez CF, Patarroyo ME, Trujillo E, et al. Owl monkey MHC-DRB exon 2 reveals high similarity with several HLA-DRB lineages. Immunogenetics 2006;58(7):542-58
   PubMed Web of Science ®Google Scholar
• Castillo F, Guerrero C, Trujillo E, et al. Identifying and structurally characterizing CD1b in Aotus nancymaae owl monkeys. Immunogenetics 2004;56(7):480-9
   PubMed Web of Science ®Google Scholar
• Moncada CA, Guerrero E, Cardenas P, et al. The T-cell receptor in primates: identifying and sequencing new owl monkey TRBV gene sub-groups. Immunogenetics 2005;57(1-2):42-52
   PubMed Web of Science ®Google Scholar
• Guerrero JE, Pacheco DP, Suarez CF, et al. Characterizing T-cell receptor gamma-variable gene in Aotus nancymaae owl monkey peripheral blood. Tissue Antigens 2003;62(6):472-82
   PubMed Web of Science ®Google Scholar
• Espejo F, Cubillos M, Salazar LM, et al. Structure, Immunogenicity, and Protectivity Relationship for the 1585 Malarial Peptide and Its Substitution Analogues. Angew Chem Int Ed Engl 2001;40(24):4654-7
   PubMed Web of Science ®Google Scholar
• Guzman F, Jaramillo K, Salazar LM, et al. 1H-NMR structures of the Plasmodium falciparum 1758 erythrocyte binding peptide analogues and protection against malaria. Life Sci 2002;71(23):2773-85
   PubMed Web of Science ®Google Scholar
• Purmova J, Salazar LM, Espejo F, et al. NMR structure of Plasmodium falciparum malaria peptide correlates with protective immunity. Biochim Biophys Acta 2002;1571(1):27-33
   PubMed Web of Science ®Google Scholar
• Sturchler D, Berger R, Rudin C, et al. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults. Am J Trop Med Hyg 1995;53(4):423-31
   PubMed Web of Science ®Google Scholar
• Herrington DA, Clyde DF, Davis JR, et al. Human studies with synthetic peptide sporozoite vaccine (NANP)3-TT and immunization with irradiated sporozoites. Bull World Health Organ 1990;68(Suppl):33-7
   PubMed Web of Science ®Google Scholar
• Patthy L. Protein evolution. 2nd edition. Blackwell Publishing Ltd; 1999
   Google Scholar
• Allen PM, Matsueda GR, Adams S, et al. Enhanced immunogenicity of a T cell immunogenic peptide by modifications of its N and C termini. Int Immunol 1989;1(2):141-50
   PubMedGoogle Scholar
• Patarroyo ME, Alba MP, Vargas LE, et al. Peptides inducing short-lived antibody responses against Plasmodium falciparum malaria have shorter structures and are read in a different MHC II functional register. Biochemistry 2005;44(18):6745-54
   PubMed Web of Science ®Google Scholar
• Patarroyo ME, Patarroyo MA. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines. Acc Chem Res 2008;41(3):377-86
   PubMed Web of Science ®Google Scholar
• Cifuentes G, Bermudez A, Rodriguez R, et al. Shifting the polarity of some critical residues in malarial peptides’ binding to host cells is a key factor in breaking conserved antigens’ code of silence. Med Chem 2008;4(3):278-92
   PubMed Web of Science ®Google Scholar
• Satterthwait AC, Chiang LC, Arrhenius T, et al. The conformational restriction of synthetic vaccines for malaria. Bull World Health Organ 1990;68(Suppl):17-25
   PubMed Web of Science ®Google Scholar
• Alba MP, Salazar LM, Purmova J, et al. Induction and displacement of a helix in the 6725 SERA peptide analogue confers protection against P. falciparum malaria. Vaccine 2004;22(9-10):1281-9
   PubMed Web of Science ®Google Scholar
• Patarroyo ME, Cifuentes G, Martinez NL, et al. Atomic fidelity of subunit-based chemically-synthesized antimalarial vaccine components. Prog Biophys Mol Biol 2010;102(1):38-44
   PubMed Web of Science ®Google Scholar
• Hamaoka BY, Ghosh P. Structure of the essential Plasmodium host cell traversal protein SPECT1. PLoS One 2014;9(12):e114685
   PubMed Web of Science ®Google Scholar
• Patarroyo ME, Alba MP, Reyes C, et al. The Malaria Parasite’s Achilles’ Heel: Functionally-relevant Invasion Structures. Curr Issues Mol Biol 2015;18:11-20
   PubMed Web of Science ®Google Scholar
• Tolia NH, Enemark EJ, Sim BK, et al. Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum. Cell 2005;122(2):183-93
   PubMed Web of Science ®Google Scholar
• Salazar LM, Alba MP, Torres MH, et al. Protection against experimental malaria associated with AMA-1 peptide analogue structures. FEBS Lett 2002;527(1-3):95-100
   PubMed Web of Science ®Google Scholar
• Alba MP, Salazar LM, Vargas LE, et al. Modifying RESA protein peptide 6671 to fit into HLA-DRbeta1* pockets induces protection against malaria. Biochem Biophys Res Commun 2004;315(4):1154-64
   PubMed Web of Science ®Google Scholar
• Patarroyo ME, Bermudez A, Alba MP. The high immunogenicity induced by modified sporozoites’ malarial peptides depends on their phi (varphi) and psi (psi) angles. Biochem Biophys Res Commun 2012;429(1-2):81-6
   PubMed Web of Science ®Google Scholar
• Patarroyo ME, Moreno-Vranich A, Bermudez A. Phi (Phi) and psi (Psi) angles involved in malarial peptide bonds determine sterile protective immunity. Biochem Biophys Res Commun 2012;429(1-2):75-80
   PubMed Web of Science ®Google Scholar
• Adzhubei AA, Sternberg MJ. Left-handed polyproline II helices commonly occur in globular proteins. J Mol Biol 1993;229(2):472-93
   PubMed Web of Science ®Google Scholar
• Adzhubei AA, Sternberg MJ, Makarov AA. Polyproline-II helix in proteins: structure and function. J Mol Biol 2013;425(12):2100-32
   PubMed Web of Science ®Google Scholar
• Patarroyo ME, Cifuentes G, Vargas LE, et al. Structural modifications enable conserved peptides to fit into MHC molecules thus inducing protection against malaria. ChemBioChem 2004;5(11):1588-93
   PubMed Web of Science ®Google Scholar
• Bermudez A, Vanegas M, Patarroyo ME. Structural and immunological analysis of circumsporozoite protein peptides: a further step in the identification of potential components of a minimal subunit-based, chemically synthesised antimalarial vaccine. Vaccine 2008;26(52):6908-18
   PubMed Web of Science ®Google Scholar
• Patarroyo ME, Cifuentes G, Pirajan C, et al. Atomic evidence that modification of H-bonds established with amino acids critical for host-cell binding induces sterile immunity against malaria. Biochem Biophys Res Commun 2010;394(3):529-35
   PubMed Web of Science ®Google Scholar
• Patarroyo ME, Cifuentes G, Rodriguez R. Structural characterisation of sporozoite components for a multistage, multi-epitope, anti-malarial vaccine. Int J Biochem Cell Biol 2008;40(3):543-57
   PubMed Web of Science ®Google Scholar
• Patarroyo ME, Almonacid H, Moreno-Vranich A. The role of amino acid electron-donor/acceptor atoms in host-cell binding peptides is associated with their 3D structure and HLA-binding capacity in sterile malarial immunity induction. Biochem Biophys Res Commun 2012;417(3):938-44
   PubMed Web of Science ®Google Scholar
• Rath A, Davidson AR, Deber CM. The structure of "unstructured" regions in peptides and proteins: role of the polyproline II helix in protein folding and recognition. Biopolymers 2005;80(2-3):179-85
   PubMed Web of Science ®Google Scholar
• Stern LJ, Brown JH, Jardetzky TS, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994;368(6468):215-21
   PubMed Web of Science ®Google Scholar
• Smith KJ, Pyrdol J, Gauthier L, et al. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J Exp Med 1998;188(8):1511-20
   PubMed Web of Science ®Google Scholar
• Dessen A, Lawrence CM, Cupo S, et al. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 1997;7(4):473-81
   PubMed Web of Science ®Google Scholar
• Patarroyo MA, Bermudez A, Lopez C, et al. 3D analysis of the TCR/pMHCII complex formation in monkeys vaccinated with the first peptide inducing sterilizing immunity against human malaria. PLoS One 2010;5(3):e9771
   PubMed Web of Science ®Google Scholar
• Ghosh P, Amaya M, Mellins E, et al. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995;378(6556):457-62
   PubMed Web of Science ®Google Scholar
• Jardetzky TS, Brown JH, Gorga JC, et al. Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Proc Natl Acad Sci U S A 1996;93(2):734-8
   PubMed Web of Science ®Google Scholar
• Rossmeisl J, Kristensen I, Gregersen M, et al. Beta-sheet preferences from first principles. J Am Chem Soc 2003;125(52):16383-6
   PubMed Web of Science ®Google Scholar
• Patarroyo ME, Bermudez A, Alba MP, et al. IMPIPS: The immune protection-inducing protein structure concept in the search for steric-electron and topochemical principles for complete fully-protective chemically synthesised vaccine development. PLoS One 2015;10(4):e0123249
   PubMed Web of Science ®Google Scholar
• Bermudez A, Calderon D, Moreno-Vranich A, et al. Gauche(+) side-chain orientation as a key factor in the search for an immunogenic peptide mixture leading to a complete fully protective vaccine. Vaccine 2014;32(18):2117-26
   PubMed Web of Science ®Google Scholar
• Fattom A, Cho YH, Chu C, et al. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine 1999;17(2):126-33
   PubMed Web of Science ®Google Scholar
• Hunt JD, Jackson DC, Brown LE, et al. Antigenic competition in a multivalent foot rot vaccine. Vaccine 1994;12(5):457-64
   PubMed Web of Science ®Google Scholar
• Sedegah M, Charoenvit Y, Minh L, et al. Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Ther 2004;11(5):448-56
   PubMed Web of Science ®Google Scholar
• Marti M, Good RT, Rug M, et al. Targeting malaria virulence and remodeling proteins to the host erythrocyte. Science 2004;306(5703):1930-3
   PubMed Web of Science ®Google Scholar
• Tossavainen H, Pihlajamaa T, Huttunen TK, et al. The layered fold of the TSR domain of P. falciparum TRAP contains a heparin binding site. Protein Sci 2006;15(7):1760-8
   PubMed Web of Science ®Google Scholar
• Hadders MA, Beringer DX, Gros P. Structure of C8alpha-MACPF reveals mechanism of membrane attack in complement immune defense. Science 2007;317(5844):1552-4
   PubMed Web of Science ®Google Scholar
• Patarroyo ME, Alba MP, Curtidor H. Biological and structural characteristics of the binding peptides from the sporozoite proteins essential for cell traversal (SPECT)-1 and -2. Peptides 2011;32(1):154-60
   PubMed Web of Science ®Google Scholar
• Pizarro JC, Chitarra V, Verger D, et al. Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate. J Mol Biol 2003;328(5):1091-103
   PubMed Web of Science ®Google Scholar
• Hodder AN, Malby RL, Clarke OB, et al. Structural insights into the protease-like antigen Plasmodium falciparum SERA5 and its noncanonical active-site serine. J Mol Biol 2009;392(1):154-65
   PubMed Web of Science ®Google Scholar
• Bermudez A, Moreno-Vranich A, Patarroyo ME. Protective immunity provided by a new modified SERA protein peptide: its immunogenetic characteristics and correlation with 3D structure. Amino Acids 2012;43(1):183-94
   PubMed Web of Science ®Google Scholar